Spirogen has a range of products in its pre-clinical development pipeline and one compound, SG2000 in Phase II clinical trials.
| Agent | Type | Stage of development | |||
|---|---|---|---|---|---|
| Discovery | Pre-clinical | Phase I | Phase II | ||
| SG2000 | Oncology |
|
|||
| SG2285 | Oncology |
|
|||
| AS-1-145 (Centanamycin) | Oncology |
|
|||
| Conjugated PBD platform | Drug-conjugates |
|
|||